{
  "$schema": "folio-library-entry/v1",
  "id": "10665-332907",
  "blocks": [
    {
      "id": "library/10665-332907/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "Cover photo of a young child in a green vest lying in the arms of an adult wearing a red and yellow patterned sari and bangles, looking toward the camera.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 6,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "TECHNICAL BRIEF — JULY 2020\nPACKAGE OF CARE FOR CHILDREN \nAND ADOLESCENTS WITH ADVANCED \nHIV DISEASE: STOP AIDS\nTECHNICAL BRIEF — JULY 2020\nPACKAGE OF CARE FOR CHILDREN \nAND ADOLESCENTS WITH ADVANCED \nHIV DISEASE: STOP AIDS\nPackage of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief\nISBN 978-92-4-000804-5 (electronic version)\nISBN 978-92-4-000805-2 (print version)\n© World Health Organization 2020\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike \n3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of the July 2020 WHO technical brief setting out a Stop AIDS care package for children and adolescents whose HIV disease is advanced, with ISBNs, copyright licence, disclaimers and a table of contents covering screening, treatment, optimization, prevention, implementation and research gaps.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ABBREVIATIONS",
      "pageStart": 6,
      "pageEnd": 7,
      "target": "../sections/sec-000-abbreviations.md",
      "narrative": null,
      "content": "BCG\nBacille Calmette-Guérin\nDTG\ndolutegravir\nEFV\nefavirenz\nE\nethambutol\nH\nisoniazid\nHPV\nhuman papillomavirus\nLF-LAM\nlateral flow urine lipoarabinomannan\nLPV/r\nlopinavir/ritonavir\nR\nrifampicin\nTB\ntuberculosis\nZ\npyrazinamide",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations used in the brief, mainly antiretroviral and tuberculosis drug names and tests.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ACKNOWLEDGEMENTS",
      "pageStart": 7,
      "pageEnd": 9,
      "target": "../sections/sec-001-acknowledgements.md",
      "narrative": null,
      "content": "The Global HIV, Hepatitis and STIs Programme of WHO gratefully acknowledges the contributions of \nmany individuals and organizations to developing this policy brief.\nLisa Frigati led the development of the brief with the contribution of several partners and experts: \nNandita Sugandhi (ICAP, Columbia University); Eleanor Magongo (Ministry of Health, Uganda), \nYusuf Bhamu, Martina Casenghi, Jennifer Cohn, Judith Kose, Barry Longwe, Lynne Mofenson, Regina \nNakiranda and Maryanne Ombija (Elizabeth Glaser Pediatric AIDS Foundation); Ikechukwu Amamilo, \nJason Brophy, Naoko Doi, Herb Harwell and Bria",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the WHO programme staff, partner organizations and experts who contributed to the technical brief on advanced HIV disease in children and adolescents. It names contributors from bodies such as ICAP, the Elizabeth Glaser Pediatric AIDS Foundation, the Clinton Health Access Initiative and Médecins Sans Frontières.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/figure-img-p009-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../images/img-p009-1.webp",
      "narrative": "draft",
      "content": "Photo of three smiling young people sitting close together against a green wall; the woman in the middle wears a T-shirt reading 'Start Free, Stay Free, AIDS Free'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "BACKGROUND",
      "pageStart": 9,
      "pageEnd": 10,
      "target": "../sections/sec-002-background.md",
      "narrative": null,
      "content": "The major causes of morbidity and mortality \namong children living with HIV in low- and \nmiddle-income countries are pneumonia \n(including Pneumocystis pneumonia), \ntuberculosis (TB), bloodstream infections, \ndiarrhoeal disease and severe acute malnutrition \n(1,2). In addition, for adolescents living with \nHIV, adult-type opportunistic infections also \noccur, including cryptococcal meningitis (3,4). \nWHO published guidelines on the management \nof advanced HIV disease in 2017, promoting a \npackage of interventions to prevent, identify \nand treat HIV-associated infections among \npeople with adva",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the main causes of illness and death in children with HIV in low- and middle-income countries, such as pneumonia, TB and malnutrition, and explains that the brief builds on WHO's 2017 advanced HIV disease guidelines. It notes that many interventions also apply to children without advanced disease.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Current WHO guidelines on managing advanced HIV disease",
      "pageStart": 10,
      "pageEnd": 13,
      "target": "../sections/sec-003-current-who-guidelines-on-managing-advanced-hiv.md",
      "narrative": null,
      "content": "advanced HIV disease\nIn 2017, WHO published guidelines for managing \nadvanced HIV disease and rapid initiation of \nantiretroviral therapy (5). Advanced HIV disease \nis defined as WHO stage 3 or 4 or a CD4 cell \ncount <200 cells/mm3 for children five years or \nolder. \nAll children younger than five years are \nconsidered to have advanced disease (5). This \nis based on the rationale that most children \nyounger than five years usually present for care \nwith advanced immunosuppression, younger \nchildren have an increased risk of disease \nprogression and mortality regardless of clinical \nand immune",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes WHO's 2017 guidance on advanced HIV disease, defining it for children and noting that all children under five are considered to have advanced disease, with exceptions for those stable on treatment. It explains that the evidence base comes mainly from adult trials such as REMSTART and REALITY. It then outlines the screening, prophylaxis and treatment recommendations relevant to children and adolescents, including that cryptococcal screening is not advised under age 10.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Screening, diagnosis and prevention components of the package of care for children and adolescents with advanced HIV disease",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table lists the screening and diagnosis, and prevention, prophylaxis and pre-emptive treatment components of the package of care for children and adolescents with advanced HIV disease, indicating (Yes/No) whether each applies to children aged <5, 5–9 and 10–19 years.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/figure-img-p013-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../images/img-p013-1.webp",
      "narrative": "draft",
      "content": "Photo of a young girl in a pink dress standing on a concrete floor beside a half-open metal door, with adults standing nearby in the light from outside.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "SCREEN",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-004-screen.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tuberculosis",
      "pageStart": 13,
      "pageEnd": 15,
      "target": "../sections/sec-005-tuberculosis.md",
      "narrative": null,
      "content": "The incidence of TB in a cohort of children living \nwith HIV in Uganda and Zimbabwe ranged from \n1.2 to 8.8 per 100 child-years, and an estimated \n15% of children starting antiretroviral therapy in \nsub-Saharan Africa develop TB (14,15). Although \nantiretroviral therapy reduces children’s risk of \nTB infection, its full protective potential is only \nevident 1–2 years after starting antiretroviral \ntherapy (8). TB is especially common in the \nfirst three months after starting antiretroviral \ntherapy (16).\nCareful history (including contact history) \nand examination should be performed for all",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the high incidence of TB in children with HIV and the symptoms used to screen for it, noting the overlap with other HIV-related signs. It covers the limits of urine LF-LAM testing in children, the 2019 LAM recommendations and the advantages of rapid molecular tests such as Xpert MTB/RIF, while stressing the continuing role of clinical diagnosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cryptococcal disease",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-006-cryptococcal-disease.md",
      "narrative": null,
      "content": "In contrast to adults, cryptococcal disease is \nrare, especially among children younger than \nfive years of age. In a laboratory-based survey \nperformed in South Africa, the incidence of \ncryptococcal disease was estimated to be 47 per \n100 000 children living with HIV in 2007 (26), \nand within two trial cohorts of children living \nwith HIV, no cases of cryptococcal disease were \nreported for children younger than five years \n(27). Screening for cryptococcal antigen and pre-\nemptive therapy is therefore only recommended \nfor adolescents.\nUseful resources\nRapid communication: molecular assays a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that cryptococcal disease is rare in young children with HIV, so antigen screening is recommended only for adolescents, and lists useful WHO resources on TB diagnostics and HIV guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TREAT",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-007-treat.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tuberculosis",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-008-tuberculosis.md",
      "narrative": null,
      "content": "Treatment for drug-sensitive TB among children \ncomprises a four-drug regimen that includes \nrifampicin (R), isoniazid (H), pyrazinamide (Z) \nand ethambutol (E). A child-friendly, fixed-\ndose combination, dispersible tablet of RHZ \nis available and can be taken with a 100-mg \nchild friendly formulation of E (intensive-phase \ntreatment). In addition, there is a child-friendly, \ndispersible fixed-dose combination of RH for \nthe continuation phase of treatment. All these \nformulations are available through the Global \nDrug Facility and should be implemented \nto alleviate the pill burden among chi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes child-friendly fixed-dose TB treatment formulations and how to manage drug interactions between rifampicin and lopinavir/ritonavir or dolutegravir in children with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Severe pneumonia",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-009-severe-pneumonia.md",
      "narrative": null,
      "content": "In studies of severe pneumonia among children \nliving with HIV, the most common bacterial \npathogens isolated were predominantly \nStreptococcus pneumoniae and Staphylococcus \naureus, pathogens that may be effectively \ncovered by commonly available and \nrecommended antibacterial medications (29). The \nseverity of illness and need for hospitalization \nshould be classified according to the WHO \nintegrated management of childhood illness \nalgorithms (30).\nThe use of intravenous or oral co-trimoxazole, \n5 mg of trimethoprim and 25 mg of \nsulfamethoxazole per kg per dose, every six hours \nfor 21 day",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers the bacterial causes of severe pneumonia in children with HIV, classification by IMCI algorithms and high-dose co-trimoxazole for suspected Pneumocystis pneumonia in young infants. It notes that for children aged one to five, standard WHO antibiotics are preferred over co-trimoxazole.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Severe bacterial infections",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-010-severe-bacterial-infections.md",
      "narrative": null,
      "content": "High rates of bacteraemia have been described \nin children starting antiretroviral therapy, \nespecially within the first three months of \ntreatment (35,36). A recent study of 82 children \nwith malnutrition admitted to a tertiary \nhospital in Durban, South Africa showed that \n6% of admission blood cultures were positive. \nCommunity-associated infections were primarily \nStreptococcus or Staphylococcus. Health \ncare-associated infections were predominantly \ngram-negative (39 of 43, 91%). No pathogen \nwas specifically associated with mortality \n(37). Salmonella is also a common cause of \nbacteraem",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes high rates of bacteraemia in children starting antiretroviral therapy and the pathogens involved, advising treatment according to WHO guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cryptococcal meningitis",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-011-cryptococcal-meningitis.md",
      "narrative": null,
      "content": "Guidelines for cryptococcal meningitis treatment \nhave been revised, and a short-course (one-\nweek) induction regimen with amphotericin B \ndeoxycholate (1.0 mg/kg per day) and flucytosine \n(100 mg/kg per day, divided into four doses per \nday) is the preferred option for children living \nwith HIV. Further recommendations are available \nin the 2018 WHO guidelines (13).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the preferred one-week amphotericin B and flucytosine induction regimen for cryptococcal meningitis in children with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Malnutrition",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-012-malnutrition.md",
      "narrative": null,
      "content": "Severe acute malnutrition is common at HIV \ndiagnosis and carries a high risk of mortality. \nThe availability of malnutrition treatment \nprogrammes and commodities, including ready-\nto-use therapeutic food where appropriate, can \nbe considered as essential components of HIV \ntreatment programmes for children.\nUseful resources\nWHO, UNICEF. Statement on the use of child-friendly \nfixed-dose combinations for the treatment of TB \nin children. Geneva: World Health Organization; \n2017 (https://www.who.int/tb/publications/\nChildTbStatementfixed-dose combinations/en)\nPneumonia and bloodstream infectio",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that severe acute malnutrition is common and deadly at HIV diagnosis and that malnutrition treatment should be part of children's HIV programmes. It then lists useful resources on child TB formulations, pneumonia management and malnutrition.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "OPTIMIZE",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-013-optimize.md",
      "narrative": null,
      "content": "In a randomized trial from South Africa, young \nchildren living with HIV (median age 23 months) \nwith severe acute malnutrition were randomized \nto receive antiretroviral therapy within 14 days \nof admission or for antiretroviral therapy to be \ndelayed until nutritional recovery (and after two \nweeks; median time 23 days) (39). The results \nsuggested that a short delay in antiretroviral \ntherapy initiation during early treatment of \nacute malnutrition resulted in improved immune \nrecovery, led to more rapid viral suppression \nand improved anthropometric measures \n(39). In another randomized tr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews trials from South Africa and Kenya on the timing of antiretroviral therapy in children with severe acute malnutrition or hospitalization. It also stresses the risk of loss to follow-up and the need to link children to ongoing HIV care at discharge.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Counselling and support",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-014-counselling-and-support.md",
      "narrative": null,
      "content": "Additional counselling and support are needed \nwith earlier antiretroviral therapy initiation. \nCounselling tools have been updated to reflect \nnewer optimal regimens and formulations. \nAdolescents generally face challenges in \nadhering to medication, and adolescent-\nfriendly services, including enhanced adherence \ncounselling, adolescent peer counsellors and \nsupport groups, may be especially valuable.\nUseful resources\nUpdate of recommendations on first- and second-line \nantiretroviral regimens: policy brief. Geneva: World \nHealth Organization; 2019 (https://www.who.int/hiv/\npub/arv/arv-updat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for more counselling and adolescent-friendly adherence support with earlier treatment initiation, and lists counselling resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PREVENT",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-015-prevent.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preventing TB, Pneumocystis pneumonia, bacterial infections and cryptococcal disease",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-016-preventing-tb-pneumocystis-pneumonia-bacterial-i.md",
      "narrative": null,
      "content": "bacterial infections and cryptococcal \ndisease\nTuberculosis\nTB preventive treatment has been shown to \nreduce morbidity and mortality among children \nliving with HIV one year and older even if they do \nnot have a known TB contact (41). Despite this, \nTB preventive treatment has not yet been fully \nimplemented as part of comprehensive HIV care \nfor children and adolescents (42). TB preventive \ntreatment is currently not recommended for \ninfants living with HIV younger than 12 months \nof age unless they have a known TB contact \n(43). This recommendation is based on evidence \nshowing that TB prev",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers TB preventive treatment for children with HIV, including the restricted use in infants without a TB contact and the preferred six-month isoniazid regimen with pyridoxine. It describes shorter rifampicin- or rifapentine-based options, their interactions with antiretroviral drugs in a summary table, and related resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. TB preventive therapy options and their drug-drug interaction with antiretrovirals used in children and adolescents with HIV",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table shows, for four TB preventive treatment regimens (6H, 3RH, 3HP, 1HP), whether they have a drug–drug interaction with the antiretrovirals LPV/r, EFV and DTG used in children and adolescents with HIV.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PCP and other infections",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-017-pcp-and-other-infections.md",
      "narrative": null,
      "content": "Co-trimoxazole\nStudies done in South Africa and Zambia in the \nera before antiretroviral therapy showed a high \nprevalence of Pneumocystis pneumonia, with \ninfants younger than six months being especially \nvulnerable regardless of CD4 cell count (44,45). \nDespite improved access to antiretroviral \ntherapy, Pneumocystis pneumonia remains a \ncommon cause of hospitalization because of \nundiagnosed HIV among infants. Cotrimoxazole \nhas been shown to prevent Pneumocystis \npneumonia, bacterial infections, toxoplasmosis \nand malaria in endemic regions (46). Children \nin Uganda and Zimbabwe were rando",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews evidence on co-trimoxazole prophylaxis to prevent Pneumocystis pneumonia and other infections in children with HIV and when it may be stopped. It also addresses fluconazole and cryptococcal antigen screening for adolescents, including lumbar puncture for those who test positive.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccinations",
      "pageStart": 21,
      "pageEnd": 25,
      "target": "../sections/sec-018-vaccinations.md",
      "narrative": null,
      "content": "The WHO 2017 advanced HIV disease guidelines \n(5) highlighted the importance of vaccination in \npreventing severe disease among people living \nwith HIV. Several other important vaccines \nwere specifically recommended, including \nmeningococcal, polio, rotavirus and yellow \nfever; however, this publication focuses on \nimmunizations for the vaccine-preventable \ninfections that are most significant to children \nliving with HIV: TB, human papillomavirus (HPV) \nmeasles and pneumococcus.\nBCG\n\t\n■Neonates born to women of unknown HIV \nstatus should be vaccinated, since the benefits \nof BCG vaccination",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out vaccination guidance for children with HIV, focusing on BCG, human papillomavirus, measles and pneumococcal vaccines, including timing relative to antiretroviral therapy and immune recovery. It notes differences in BCG practice between countries and gives revaccination and catch-up advice. A case study describes scaling up the advanced HIV disease package for children in Malawi using a hub-and-spoke model and the challenges encountered.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. Prophylactic doses of drugs for children based on weight bands: daily administration",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "The table gives daily prophylactic doses of co-trimoxazole, isoniazid, the isoniazid/co-trimoxazole/vitamin B6 combination and fluconazole for children: for each drug and formulation, the recommended daily dose and the dose to give in each of seven weight bands from 3 kg to over 30 kg.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/figure-img-p022-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../images/img-p022-1.webp",
      "narrative": "draft",
      "content": "Photo of two health workers in a clinic office sorting supplies on a table, including medicine bottles and a 'Flip Chart'; the walls are covered with notices and posters and the shelves with files.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/figure-img-p024-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../images/img-p024-1.webp",
      "narrative": "draft",
      "content": "Photo of a health worker leaning over a desk and writing in a large paper register next to a small card, with a child seated beside the desk and a tablet on the table.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "IMPLEMENTATION CONSIDERATIONS",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-019-implementation-considerations.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "National level",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-020-national-level.md",
      "narrative": null,
      "content": "■The recommendations in the 2017 guidelines on advanced HIV disease (5) (and other related \nupdated WHO guidelines) need to be adopted in national policy and guidelines.\n\t\n■It is important to try to align recommendations across multiple guidelines relating not only \nto HIV (for example, TB and HIV guidelines relating to TB preventive treatment) but also to \nroutine child health and development interventions (vitamin A, deworming and Expanded \nProgramme on Immunization).\n\t\n■Registration and procurement of the required commodities and medication (especially \nformulations for children) are vital",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists national-level implementation steps, such as adopting the guidelines, aligning HIV, TB and child health guidance, procuring child formulations and enabling catch-up vaccination.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Facility level",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-021-facility-level.md",
      "narrative": null,
      "content": "■Currently, the advanced HIV disease package is being implemented as a hub-and-spoke model. \nFurther guidance on this is available in the global advanced HIV disease toolkit (http://www.\ndifferentiatedcare.org/Resources/Resource-Library/Global-Advanced-HIV-DiseaseToolkit).\n\t\n■In the context of ongoing and enhanced efforts to ensure task shifting for services for children, \nall cadres of health-care workers need training for certain components of the package such as \nscreening and enhanced antiretroviral therapy counselling.\n\t\n■Centres introducing the advanced HIV disease package for children s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists facility-level considerations for the paediatric advanced HIV disease package, including hub-and-spoke delivery, task shifting, child-friendly settings and equipment. It also stresses functioning referral systems, for example for safe administration of amphotericin B.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Health-care providers",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-022-health-care-providers.md",
      "narrative": null,
      "content": "■Health-care providers should be sensitized on child-specific issues such as growth monitoring \nand other routine child health interventions.\n\t\n■Training and capacity building for staff should be implemented in sites where these \nrecommendations are to be implemented.\n\t\n■Ensure that the advanced HIV disease package is included in any curriculum of training on HIV \nrelated to children or adolescents.\n\t\n■Uptake of TB screening specific to children is challenging. Ensure appropriate adaptation of \nexisting screening tools for the advanced HIV disease package that focus on the different ways \nthat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists actions for health-care providers, such as training on child health issues and paediatric TB screening, and stresses that clinical diagnosis and treatment of TB should continue when tests are unavailable or negative.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Laboratory",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-023-laboratory.md",
      "narrative": null,
      "content": "■Ensure that protocols and standard operating procedures are in place for obtaining and \ntransporting specimens from young children. Training and expertise in paediatric phlebotomy \nand ordering urine bags, gastric washings, sputum induction and stool collection and \nprocessing need to be considered.\n\t\n■Explore the capacity for antibiotic resistance surveillance to ensure that the optimal first-line \ntreatment for severe bacterial infections is being used.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for laboratory procedures for collecting specimens from young children and for antibiotic resistance surveillance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring and evaluation",
      "pageStart": 26,
      "pageEnd": 28,
      "target": "../sections/sec-024-monitoring-and-evaluation.md",
      "narrative": null,
      "content": "■Monitor the potential toxicity of children receiving TB preventive treatment, co-trimoxazole \nplus antiretroviral therapy (and potentially fluconazole for adolescents).\n\t\n■Monitoring tools need to be developed for the advanced HIV disease package that are specific \nto children.\nTable 4. Cost implications and considerations for commodities\nMedicines (dosage form and pack size)\nReference price excluding \ntransport (USD)\nSourcea\nTB and co-trimoxazole preventive therapy in HIV\nIsoniazid, 300-mg tablet, 30\n0.75\nGlobal Fund Pooled Procurement Mechanism\nIsoniazid, 100-mg tablet, 100b\n1.29\nGlobal Fun",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for monitoring the toxicity of combined preventive therapies and for child-specific monitoring tools. Table 4 lists reference prices and sources for key commodities in the package, such as isoniazid and co-trimoxazole, followed by useful resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4. Cost implications and considerations for commodities",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "The table lists reference prices (USD, excluding transport) and procurement sources for medicines used for TB and co-trimoxazole preventive therapy and for cryptococcal disease, followed by a second block for diagnostic tests.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "RESEARCH GAPS",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/sec-025-research-gaps.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Clinical research",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/sec-026-clinical-research.md",
      "narrative": null,
      "content": "Diagnostics\n\t\n■Research gaps related to diagnostics in children include the need to develop simplified point-\nof-care diagnostics for pneumonia, specifically Pneumocystis pneumonia and cytomegalovirus \ndisease.\n\t\n■In addition, the use of rapid molecular tests in stools and other urine LAM assays needs to be \nfurther evaluated in children.\nProphylaxis\n\t\n■Whether there is an optimal package of prophylactic interventions for children living with HIV \nyounger than five years has yet to be determined. This may focus on bacterial infections and \nspecifically on the benefit of azithromycin.\n\t\n■TB pre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists clinical research gaps in diagnostics, prophylaxis and treatment for children with advanced HIV disease, such as point-of-care pneumonia tests, the role of azithromycin and shorter TB preventive regimens. It also mentions ongoing studies of cryptococcal meningitis treatment that may inform care of older children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Operational research",
      "pageStart": 28,
      "pageEnd": 29,
      "target": "../sections/sec-027-operational-research.md",
      "narrative": null,
      "content": "■TB diagnosis and prevention is being studied in several countries in Africa in the Catalyzing \nPediatric Tuberculosis Innovations programme (https://unitaid.org/assets/Catalyzing-Pediatric-\nTuberculosis-Innovations-CaP-TB.pdf). Enhanced early detection of TB is being studied in the \nTB-Speed study in seven countries in Africa and Asia (https://www.tb-speed.com). A publication \non research priorities for children with TB (https://www.treatmentactiongroup.org/publication/\nresearch-priorities-for-pediatric-tuberculosis).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists ongoing operational research on paediatric TB diagnosis and prevention, such as the CaP TB programme and the TB-Speed study.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REFERENCES",
      "pageStart": 29,
      "pageEnd": 32,
      "target": "../sections/sec-028-references.md",
      "narrative": null,
      "content": "1.\t\nFord N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among \npeople living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–44.\n2.\t\nWalker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A et al. Mortality in the year following \nantiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. \n2012;55:1707–18.\n3.\t\nLowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired \nHIV infection in adolescents from su",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list of the 2020 technical brief on advanced HIV disease in children, citing studies on hospital admissions, mortality, TB, opportunistic infections and vaccination in children with HIV, followed by WHO HIV department contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-332907/blocks/figure-img-p032-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../images/img-p032-1.webp",
      "narrative": "draft",
      "content": "Back-cover photo of a woman in an orange embroidered sari seen from behind in a dark doorway, carrying a sleeping young child on her shoulder, framed by pink walls and a teal metal door.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-332907/blocks/figure-img-p032-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../images/img-p032-2.webp",
      "narrative": "draft",
      "content": "ISBN barcode with the number 9789240008045.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
